Back to today’s briefing

Story perspectives

Hims & Hers Sees 69% Revenue Surge to $1.47B

4/4/2025

23 2

Summary

Hims & Hers Soars

Hims & Hers is soaring to new heights, projecting a remarkable $1.47 billion in revenue for 2024—a stunning 69% jump from the previous year. Their innovative telehealth model boosts profits, while their weight management services draw in over two million subscribers. Yet, the company must navigate fierce competition and escalating operational costs.

Summary

Hims & Hers Expands

Hims & Hers is ramping up its weight-loss offerings by introducing Eli Lilly's Zepbound and generic liraglutide. While Hims & Hers sets a steep price of $1,899 per month for Zepbound, Eli Lilly's starting price is just $349. With a goal of $725 million in weight-loss revenue by 2025, the demand for these services is undeniable, despite Eli Lilly's denial of any ties to Hims & Hers.

History

Historical Context

Hims & Hers' rise in telehealth reflects a historical trend in healthcare innovation. The 19th-century low-carb diet breakthroughs by William Banting laid groundwork for modern weight management. Today's digital platforms echo past efforts, merging technology with health, but face challenges from competition and rising costs, reminiscent of earlier market struggles.

1 of 3

Hims & Hers Soars

Hims & Hers is soaring to new heights, projecting a remarkable $1.47 billion in revenue for 2024—a stunning 69% jump from the previous year. Their innovative telehealth model boosts profits, while their weight management services draw in over two million subscribers. Yet, the company must navigate fierce competition and escalating operational costs.

1 / 3